BRPI0717067A2 - composiÇÕes farmacÊuticas aquosas autoconservadas - Google Patents

composiÇÕes farmacÊuticas aquosas autoconservadas

Info

Publication number
BRPI0717067A2
BRPI0717067A2 BRPI0717067-0A2A BRPI0717067A BRPI0717067A2 BR PI0717067 A2 BRPI0717067 A2 BR PI0717067A2 BR PI0717067 A BRPI0717067 A BR PI0717067A BR PI0717067 A2 BRPI0717067 A2 BR PI0717067A2
Authority
BR
Brazil
Prior art keywords
self
compositions
amount
balanced
present
Prior art date
Application number
BRPI0717067-0A2A
Other languages
English (en)
Inventor
Bhagwati P Kabra
Masood A Chowhan
L Wayne Schneider
Wesley Wehsin Han
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0717067(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BRPI0717067A2 publication Critical patent/BRPI0717067A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Patente de Invenção COMPOSIÇÕES FARMACEUTICAS AQUOSAS AUTOCONSERVADAS". A presente invenção refere-se á provisão de composições oftálmicas de multidose, autoconservadas. As composições possuem atMdade antimicroblana suficiente para satisfazer os requisitos de eficácia de conservantes da USP, como também padrões de conservantes similares (por exemplo, EP e JP), sem exigir a presença de agentes de conservante antimicrobiano convencional, tais como cloreto de benzalcônio. As composições são eficazmente conservadas por um sistema de tampão iônico balanceado contendo lons de zinco em uma concentração de 0,04 a 0,9 mM, preferivelmente 0,04 a 0,4 mM. Um aspecto do sistema de tampão balanceado é a limitação da quantidade de ánlons tamponados presentes em uma concentração de 15 mM ou menos, preferivelmente 5 mM ou menos. Em uma modalidade preferida, as composições também contêm borato ou, mais preferivelmente complexos de boratolpoliol. O uso de propileno glicol como o poliol em tais complexos é firmemente preferido. Limitar a quantidade de metais divalentes em vez de zinco e a quantidade de sais ionizados presentes tem também sido definido como sendo importante para maximizar a atividade antimicrobiana dos sistemas de tampão balanceados.
BRPI0717067-0A2A 2006-09-21 2007-09-20 composiÇÕes farmacÊuticas aquosas autoconservadas BRPI0717067A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82652906P 2006-09-21 2006-09-21
US82741106P 2006-09-28 2006-09-28
PCT/US2007/079082 WO2008036847A2 (en) 2006-09-21 2007-09-20 Self preserved aqueous pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BRPI0717067A2 true BRPI0717067A2 (pt) 2013-09-24

Family

ID=39156274

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717067-0A2A BRPI0717067A2 (pt) 2006-09-21 2007-09-20 composiÇÕes farmacÊuticas aquosas autoconservadas

Country Status (21)

Country Link
US (3) US8268299B2 (pt)
EP (1) EP2068822B2 (pt)
JP (2) JP4785970B2 (pt)
KR (1) KR101021933B1 (pt)
AR (1) AR062929A1 (pt)
AT (1) ATE531358T1 (pt)
AU (1) AU2007299727B2 (pt)
BR (1) BRPI0717067A2 (pt)
CA (1) CA2606370C (pt)
CL (1) CL2007002705A1 (pt)
CY (1) CY1112138T1 (pt)
DK (1) DK2068822T4 (pt)
ES (1) ES2374444T5 (pt)
MX (1) MX2009002221A (pt)
PL (1) PL2068822T5 (pt)
PT (1) PT2068822E (pt)
RU (1) RU2436568C2 (pt)
SI (1) SI2068822T2 (pt)
TW (1) TWI394564B (pt)
UY (1) UY30605A1 (pt)
WO (1) WO2008036847A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
ES2543349T5 (es) 2006-09-28 2019-06-17 Novartis Ag Composiciones farmacéuticas acuosas autoconservadas
AR066901A1 (es) * 2007-05-18 2009-09-23 Alcon Mfg Ltd Composiciones fodfolipidicas para elcuidado de lentes de contacto y conservacion de composiciones farmaceuticas
DK2420223T3 (da) † 2008-03-17 2017-11-06 Novartis Ag Vandige farmaceutiske sammensætninger med borat-polyol-komplekser
JP2009256281A (ja) * 2008-04-21 2009-11-05 Teika Seiyaku Kk イソプロピルウノプロストン含有点眼剤組成物
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
WO2010074961A1 (en) * 2008-12-22 2010-07-01 Alcon Research, Ltd. Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
BR112012014260A2 (pt) * 2009-12-15 2015-09-15 Foresight Biotherapeutics Inc composições de iodopovidona oftalmológica não irritante
TW201127423A (en) * 2009-12-17 2011-08-16 Alcon Res Ltd Ophthalmic solutions with improved disinfection profiles
CA2828635C (en) * 2011-03-04 2020-01-14 Grunenthal Gmbh Parenteral administration of tapentadol
PL3287123T3 (pl) 2011-03-04 2020-11-02 Grünenthal GmbH Wodny preparat farmaceutyczny tapentadolu do podawania doustnego
JP6150510B2 (ja) * 2011-12-12 2017-06-21 ロート製薬株式会社 眼科用水性組成物
EP2630952A1 (en) 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
TW201417814A (zh) * 2012-09-28 2014-05-16 Otsuka Pharma Co Ltd 包括瑞巴派特之醫藥組成物
US20150374820A1 (en) * 2013-02-15 2015-12-31 Senju Pharmaceutical Co., Ltd. Difluprednate emulsion composition containing zinc
CN116966162A (zh) 2013-03-13 2023-10-31 onCOUR制药股份有限公司 用于治疗炎症的免疫修饰性颗粒
EP3037094A1 (en) 2014-12-23 2016-06-29 Poifa Warszawa SA Ophthalmic pharmaceutical composition
HRP20190231T1 (hr) 2015-03-27 2019-04-05 Grünenthal GmbH Stabilna formulacija za parenteralnu primjenu tapentadola
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US10632202B2 (en) 2016-03-04 2020-04-28 Johnson & Johnson Consumer Inc. Preservative containing compositions
CA3037810A1 (en) 2016-09-23 2018-03-29 Grunenthal Gmbh Stable formulation for parenteral administration of tapentadol
WO2019123266A1 (en) 2017-12-20 2019-06-27 Novartis Ag Ophthalmic composition having a prostaglandin and a beta-blocker
BR112022015533A2 (pt) 2020-02-06 2022-09-27 Ocular Therapeutix Inc Composições e métodos para tratar doenças oculares
EP4142664A4 (en) 2020-04-27 2024-05-29 Ocular Therapeutix, Inc. METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS
US20220031739A1 (en) * 2020-07-31 2022-02-03 Eye Therapies Llc Anti-viral compositions and methods of use thereof
TW202320815A (zh) 2021-09-30 2023-06-01 日商樂敦製藥股份有限公司 眼科組成物
EP4543456A1 (en) * 2022-06-27 2025-04-30 Zaklady Farmaceutyczne "Polpharma" Spolka Akcyjna Preservative-free ophthalmic composition comprising a prostaglandin analogue
US20250381275A1 (en) 2022-07-06 2025-12-18 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
EP4309644A1 (en) * 2022-07-22 2024-01-24 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Preservative-free ophthalmic composition comprising an antiglaucoma agent

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2084870B (en) * 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US5607698A (en) * 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
IL92351A (en) * 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5221664A (en) * 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
KR0127768B1 (ko) * 1990-12-27 1997-12-26 마틴 에이. 보에트 콘택트렌즈를 살균하기 위한 방법 및 조성물
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
EP0639070B2 (en) * 1992-05-06 2010-09-08 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5320843A (en) * 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5736165A (en) * 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
TW274516B (pt) * 1993-11-12 1996-04-21 Ciba Geigy Ag
WO1996003158A1 (en) * 1994-07-22 1996-02-08 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US6024954A (en) * 1994-12-12 2000-02-15 Allergan Compositions and methods for disinfecting contact lenses and preserving contact lens care products
KR100320688B1 (ko) * 1995-03-20 2002-05-09 알 브이 테이트 (로드니 비버스 테이트), 에이치 드로이. 씨. 지. 오닌크, 이. 에디, 산드라 웨드워즈 (에스 제이 에드워즈) 액체세정제제
US5683993A (en) * 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
HU225329B1 (en) * 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
WO1998011867A1 (en) * 1996-09-20 1998-03-26 Warner-Lambert Company Oral compositions containing a zinc compound
US5820822A (en) * 1996-10-25 1998-10-13 Kross; Robert D. Antimicrobial composition and method of use
CN1157227C (zh) * 1996-12-13 2004-07-14 阿尔康实验室公司 低分子量氨基醇在眼用组合物中的应用
US5858346A (en) * 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
KR100507984B1 (ko) * 1997-07-29 2005-08-17 알콘 래보레이토리스, 인코퍼레이티드 갈락토만난 중합체 및 붕산염을 함유하는 안과용 조성물
US6034043A (en) * 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6166012A (en) * 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
CN1477929A (zh) * 2000-11-29 2004-02-25 ��˹��ŵ�� 水性消毒系统
AR035509A1 (es) * 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
JP4863589B2 (ja) † 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP2004339104A (ja) * 2003-05-14 2004-12-02 Rohto Pharmaceut Co Ltd 溶液の安定化方法
ES2561034T3 (es) * 2003-12-09 2016-02-24 Novartis Ag Uso de bis-aminas para incrementar la actividad antimicrobiana de composiciones acuosas
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
CA2545947A1 (en) * 2003-12-11 2005-07-07 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20050214382A1 (en) * 2004-03-29 2005-09-29 Erning Xia Zinc preservative composition and method of use
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US20070212420A1 (en) 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US20070297990A1 (en) * 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物

Also Published As

Publication number Publication date
JP4785970B2 (ja) 2011-10-05
JP2011246476A (ja) 2011-12-08
ES2374444T3 (es) 2012-02-16
PL2068822T3 (pl) 2012-03-30
KR20090058567A (ko) 2009-06-09
US20130053440A1 (en) 2013-02-28
CA2606370A1 (en) 2008-03-21
JP2010504358A (ja) 2010-02-12
UY30605A1 (es) 2008-03-31
WO2008036847A3 (en) 2008-05-29
ATE531358T1 (de) 2011-11-15
TWI394564B (zh) 2013-05-01
EP2068822A2 (en) 2009-06-17
US20080075790A1 (en) 2008-03-27
PT2068822E (pt) 2012-01-10
HK1126667A1 (en) 2009-09-11
ES2374444T5 (es) 2022-11-21
EP2068822B1 (en) 2011-11-02
JP5411897B2 (ja) 2014-02-12
US8268299B2 (en) 2012-09-18
CA2606370C (en) 2012-03-27
RU2009114849A (ru) 2010-10-27
TW200820962A (en) 2008-05-16
US20110195132A1 (en) 2011-08-11
US8323630B2 (en) 2012-12-04
DK2068822T3 (da) 2012-01-23
KR101021933B1 (ko) 2011-03-16
AU2007299727B2 (en) 2011-10-06
PL2068822T5 (pl) 2022-11-14
SI2068822T2 (sl) 2022-10-28
MX2009002221A (es) 2009-03-13
WO2008036847A2 (en) 2008-03-27
AU2007299727A8 (en) 2009-04-09
SI2068822T1 (sl) 2012-02-29
AR062929A1 (es) 2008-12-17
EP2068822B2 (en) 2022-07-27
DK2068822T4 (da) 2022-10-31
CY1112138T1 (el) 2015-11-04
RU2436568C2 (ru) 2011-12-20
AU2007299727A1 (en) 2008-03-27
CL2007002705A1 (es) 2008-05-16

Similar Documents

Publication Publication Date Title
BRPI0717067A2 (pt) composiÇÕes farmacÊuticas aquosas autoconservadas
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
Gottardi et al. N-chloramines, a promising class of well-tolerated topical anti-infectives
Wojtovich et al. The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channels
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
BRPI0514420A (pt) peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo
BRPI0412291A (pt) antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
BRPI0409211A (pt) composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
RU2011101713A (ru) Фармацевтическая композиция
BR122016020003B8 (pt) composição antimicrobiana compreendendo componente lipídico antimicrobiano
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
BR0313723A (pt) Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor
BRPI1015996B8 (pt) composição oftálmica de múltiplas doses contendo complexos de borato-poliol.
DE69942977D1 (de) Pharmazeutische zusammenstellungen zur behandlung von hautzuständen
MX2007010072A (es) Derivados de piperidina antibacterianos.
UA90521C2 (uk) Фармацевтична композиція, що містить симвастатин і езетиміб
EA201190286A1 (ru) Адъювантные композиции, содержащие неионный агент, обеспечивающий изотоничность
BR0208563A (pt) composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga
TR199903214T2 (xx) Bir antit�m�r maddesi ve bir hidroksimik asit t�revini ihtiva eden, antit�m�r etkinli�i artt�r�lm�� ve yan etkileri d���r�lm�� farmas�tik bile�im.
DK1392328T3 (da) Medikament til beskyttelse i radioterapi
CU23367A3 (es) Formulación de moxifloxacino con sal común
BRPI0510684A (pt) composições para adiministração tópica ou transdérmica de agente anticolinérgico ou antiespasmódico e uso dos respectivos compostos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALCON RESEARCH, LLC (US)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL